Credit: Getty Images. Significant factors limit MDMA’s ability to be used in the treatment of post-traumatic stress disorder. Significant factors limit MDMA’s ability to be used in the treatment of ...

These data represent one of the largest clinical development programs to date for adults living with PTSD and a significant development in a therapy area that hasn’t seen a new approval for a ...

According to the letter, the application could not be approved due to lack of substantial efficacy from the submitted studies. The Food and Drug Administration (FDA) has issued a Complete Response ...

Many people have interpreted as a setback the “no” vote by an advisory committee to the Food and Drug Administration on Lykos Therapeutics’ new drug application for MDMA-assisted psychotherapy for ...

LONDON & NEW YORK, January 07, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today ...

Compass Pathways has navigated to another successful midphase readout, linking its psilocybin therapy and psychological support to improvements in post-traumatic stress disorder (PTSD) in a small ...

Myriam Barthes - Journey Clinical, Inc. Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would ...

Rena Goldman has over a decade of writing and editing experience. She covers health, wellness, mental health, small business, and how politics and policies impact our daily lives. Rena has worked as a ...

When I was in medical school, senior physicians would frequently usher a group of us students into a patient’s room so we might hear them tell the story of their illness. It seemed that the more ...

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...